JAK3 in clear cell renal cell carcinoma: Mutational screening and clinical implications

Michela de Martino, Maddalena Gigante, Luigi Cormio, Clelia Prattichizzo, Elisabetta Cavalcanti, Margherita Gigante, Vincenzo Ariano, Giuseppe S. Netti, Eustacchio Montemurno, Vito Mancini, Michele Battaglia, Loreto Gesualdo, Giuseppe Carrieri, Elena Ranieri

Research output: Contribution to journalArticle

Abstract

Janus Kinase 3 (JAK3) mediates cytokine signaling and T-cell activation. We hypothesized that JAK3 mutations may contribute to the development and progression of clear cell renal cell carcinoma (ccRCC). To test this hypothesis, we performed mutational screening and functional studies. This hospital-based case-control study included 50 patients with ccRCC and 100 age- and gender-matched controls. Both genomic and tumor DNA were extracted. All 23 JAK3 exons were amplified by PCR and analyzed by denaturing high-performance liquid chromatography and automatic sequencing. Effects of mutations on interleukin-2-stimulated peripheral T-cells were analyzed by confocal laser-scanning microscopy and immunoprecipitation. Four different germline missense mutations (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Val722Ile) were found in a total of 7 ccRCC patients (14%), but in none of the controls (P = 0.0006). All germline mutations were similarly detected in the tumors. An additional somatic missense mutation (p.Tyr238Cys) was found in a patient who had a germline mutation. Four of the mutations have not been previously described (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Tyr238Cys). Patients withmutations more frequently presented with metastases (3 out of 4 [75%] vs. 4 out of 46 [9%]; = 0.004) and had poorer survival = 0.049). In p.Arg925Ser and p.Ala677Thr/p.Val722Ile, functional analyses showed abnormal JAK3 and STAT5 tyrosine phosphorylation and a reduction of JAK3/STAT5 interaction.mutations are found in a subset of ccRCC patients and may be associated with ccRCC development and a greater risk of metastases. function is compromised in p.Arg925Ser and p.Ala677Thr/p.Val722Ile. Future studies with a larger number of patients need to confirm these findings.

Original languageEnglish
Pages (from-to)930-937
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume31
Issue number6
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Janus Kinase 3
Renal Cell Carcinoma
Germ-Line Mutation
Mutation
Missense Mutation
Neoplasm Metastasis
T-Lymphocytes
Immunoprecipitation
Confocal Microscopy
Interleukin-2
Case-Control Studies
Exons
Neoplasms
High Pressure Liquid Chromatography
Phosphorylation
Cytokines
Polymerase Chain Reaction
Survival
DNA

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

JAK3 in clear cell renal cell carcinoma : Mutational screening and clinical implications. / de Martino, Michela; Gigante, Maddalena; Cormio, Luigi; Prattichizzo, Clelia; Cavalcanti, Elisabetta; Gigante, Margherita; Ariano, Vincenzo; Netti, Giuseppe S.; Montemurno, Eustacchio; Mancini, Vito; Battaglia, Michele; Gesualdo, Loreto; Carrieri, Giuseppe; Ranieri, Elena.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 31, No. 6, 08.2013, p. 930-937.

Research output: Contribution to journalArticle

de Martino, M, Gigante, M, Cormio, L, Prattichizzo, C, Cavalcanti, E, Gigante, M, Ariano, V, Netti, GS, Montemurno, E, Mancini, V, Battaglia, M, Gesualdo, L, Carrieri, G & Ranieri, E 2013, 'JAK3 in clear cell renal cell carcinoma: Mutational screening and clinical implications', Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 6, pp. 930-937. https://doi.org/10.1016/j.urolonc.2011.07.001
de Martino, Michela ; Gigante, Maddalena ; Cormio, Luigi ; Prattichizzo, Clelia ; Cavalcanti, Elisabetta ; Gigante, Margherita ; Ariano, Vincenzo ; Netti, Giuseppe S. ; Montemurno, Eustacchio ; Mancini, Vito ; Battaglia, Michele ; Gesualdo, Loreto ; Carrieri, Giuseppe ; Ranieri, Elena. / JAK3 in clear cell renal cell carcinoma : Mutational screening and clinical implications. In: Urologic Oncology: Seminars and Original Investigations. 2013 ; Vol. 31, No. 6. pp. 930-937.
@article{fe4500e6401a46c4a4ff57316bdb44dc,
title = "JAK3 in clear cell renal cell carcinoma: Mutational screening and clinical implications",
abstract = "Janus Kinase 3 (JAK3) mediates cytokine signaling and T-cell activation. We hypothesized that JAK3 mutations may contribute to the development and progression of clear cell renal cell carcinoma (ccRCC). To test this hypothesis, we performed mutational screening and functional studies. This hospital-based case-control study included 50 patients with ccRCC and 100 age- and gender-matched controls. Both genomic and tumor DNA were extracted. All 23 JAK3 exons were amplified by PCR and analyzed by denaturing high-performance liquid chromatography and automatic sequencing. Effects of mutations on interleukin-2-stimulated peripheral T-cells were analyzed by confocal laser-scanning microscopy and immunoprecipitation. Four different germline missense mutations (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Val722Ile) were found in a total of 7 ccRCC patients (14{\%}), but in none of the controls (P = 0.0006). All germline mutations were similarly detected in the tumors. An additional somatic missense mutation (p.Tyr238Cys) was found in a patient who had a germline mutation. Four of the mutations have not been previously described (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Tyr238Cys). Patients withmutations more frequently presented with metastases (3 out of 4 [75{\%}] vs. 4 out of 46 [9{\%}]; = 0.004) and had poorer survival = 0.049). In p.Arg925Ser and p.Ala677Thr/p.Val722Ile, functional analyses showed abnormal JAK3 and STAT5 tyrosine phosphorylation and a reduction of JAK3/STAT5 interaction.mutations are found in a subset of ccRCC patients and may be associated with ccRCC development and a greater risk of metastases. function is compromised in p.Arg925Ser and p.Ala677Thr/p.Val722Ile. Future studies with a larger number of patients need to confirm these findings.",
author = "{de Martino}, Michela and Maddalena Gigante and Luigi Cormio and Clelia Prattichizzo and Elisabetta Cavalcanti and Margherita Gigante and Vincenzo Ariano and Netti, {Giuseppe S.} and Eustacchio Montemurno and Vito Mancini and Michele Battaglia and Loreto Gesualdo and Giuseppe Carrieri and Elena Ranieri",
year = "2013",
month = "8",
doi = "10.1016/j.urolonc.2011.07.001",
language = "English",
volume = "31",
pages = "930--937",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - JAK3 in clear cell renal cell carcinoma

T2 - Mutational screening and clinical implications

AU - de Martino, Michela

AU - Gigante, Maddalena

AU - Cormio, Luigi

AU - Prattichizzo, Clelia

AU - Cavalcanti, Elisabetta

AU - Gigante, Margherita

AU - Ariano, Vincenzo

AU - Netti, Giuseppe S.

AU - Montemurno, Eustacchio

AU - Mancini, Vito

AU - Battaglia, Michele

AU - Gesualdo, Loreto

AU - Carrieri, Giuseppe

AU - Ranieri, Elena

PY - 2013/8

Y1 - 2013/8

N2 - Janus Kinase 3 (JAK3) mediates cytokine signaling and T-cell activation. We hypothesized that JAK3 mutations may contribute to the development and progression of clear cell renal cell carcinoma (ccRCC). To test this hypothesis, we performed mutational screening and functional studies. This hospital-based case-control study included 50 patients with ccRCC and 100 age- and gender-matched controls. Both genomic and tumor DNA were extracted. All 23 JAK3 exons were amplified by PCR and analyzed by denaturing high-performance liquid chromatography and automatic sequencing. Effects of mutations on interleukin-2-stimulated peripheral T-cells were analyzed by confocal laser-scanning microscopy and immunoprecipitation. Four different germline missense mutations (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Val722Ile) were found in a total of 7 ccRCC patients (14%), but in none of the controls (P = 0.0006). All germline mutations were similarly detected in the tumors. An additional somatic missense mutation (p.Tyr238Cys) was found in a patient who had a germline mutation. Four of the mutations have not been previously described (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Tyr238Cys). Patients withmutations more frequently presented with metastases (3 out of 4 [75%] vs. 4 out of 46 [9%]; = 0.004) and had poorer survival = 0.049). In p.Arg925Ser and p.Ala677Thr/p.Val722Ile, functional analyses showed abnormal JAK3 and STAT5 tyrosine phosphorylation and a reduction of JAK3/STAT5 interaction.mutations are found in a subset of ccRCC patients and may be associated with ccRCC development and a greater risk of metastases. function is compromised in p.Arg925Ser and p.Ala677Thr/p.Val722Ile. Future studies with a larger number of patients need to confirm these findings.

AB - Janus Kinase 3 (JAK3) mediates cytokine signaling and T-cell activation. We hypothesized that JAK3 mutations may contribute to the development and progression of clear cell renal cell carcinoma (ccRCC). To test this hypothesis, we performed mutational screening and functional studies. This hospital-based case-control study included 50 patients with ccRCC and 100 age- and gender-matched controls. Both genomic and tumor DNA were extracted. All 23 JAK3 exons were amplified by PCR and analyzed by denaturing high-performance liquid chromatography and automatic sequencing. Effects of mutations on interleukin-2-stimulated peripheral T-cells were analyzed by confocal laser-scanning microscopy and immunoprecipitation. Four different germline missense mutations (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Val722Ile) were found in a total of 7 ccRCC patients (14%), but in none of the controls (P = 0.0006). All germline mutations were similarly detected in the tumors. An additional somatic missense mutation (p.Tyr238Cys) was found in a patient who had a germline mutation. Four of the mutations have not been previously described (p.Gln13Lys; p.Arg925Ser; p.Ala677Thr, p.Tyr238Cys). Patients withmutations more frequently presented with metastases (3 out of 4 [75%] vs. 4 out of 46 [9%]; = 0.004) and had poorer survival = 0.049). In p.Arg925Ser and p.Ala677Thr/p.Val722Ile, functional analyses showed abnormal JAK3 and STAT5 tyrosine phosphorylation and a reduction of JAK3/STAT5 interaction.mutations are found in a subset of ccRCC patients and may be associated with ccRCC development and a greater risk of metastases. function is compromised in p.Arg925Ser and p.Ala677Thr/p.Val722Ile. Future studies with a larger number of patients need to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=84880702907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880702907&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2011.07.001

DO - 10.1016/j.urolonc.2011.07.001

M3 - Article

C2 - 21868263

AN - SCOPUS:84880702907

VL - 31

SP - 930

EP - 937

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 6

ER -